NCT01537900View on ClinicalTrials.gov

A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir

GZR 100 mg tablet by mouth q.d. for 7 days.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01537900 - A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) | Biotech Hunter | Biotech Hunter